TY - JOUR
T1 - Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions
AU - Sloss, Elizabeth M.
AU - Wickstrom, Steven L.
AU - McCaffrey, Daniel F.
AU - Garber, Steven
AU - Rector, Thomas S.
AU - Levin, Regina A.
AU - Guzy, Peter M.
AU - Gorelick, Philip B.
AU - Dake, Michael D.
AU - Vickrey, Barbara G.
PY - 2004
Y1 - 2004
N2 - Background: The cost of acute ischemic events in persons with established atherosclerotic conditions is unknown. Methods: The direct medical costs attributable to secondary acute myocardial infarction (AMI) or ischemic stroke among persons with established atherosclerotic conditions were estimated from 1995-1998 data on 1,143 patients enrolled in US managed care plans. Results: The average 180-day costs attributable to secondary AMI or stroke were estimated as USD 19,056 in the AMI cohort having a private insurance (commercial; n = 344), USD 16,845 in the AMI cohort having government insurance (Medicare, age ≥65 years; n = 200), USD 10,267 for stroke commercial (n = 108), USD 16,280 for stroke Medicare (n = 113), USD 15,224 for peripheral arterial disease commercial (n = 170), and USD 15,182 for peripheral arterial disease Medicare (n = 208). Conclusion: These estimates can be used to study the cost-effectiveness of interventions proven to reduce these secondary events.
AB - Background: The cost of acute ischemic events in persons with established atherosclerotic conditions is unknown. Methods: The direct medical costs attributable to secondary acute myocardial infarction (AMI) or ischemic stroke among persons with established atherosclerotic conditions were estimated from 1995-1998 data on 1,143 patients enrolled in US managed care plans. Results: The average 180-day costs attributable to secondary AMI or stroke were estimated as USD 19,056 in the AMI cohort having a private insurance (commercial; n = 344), USD 16,845 in the AMI cohort having government insurance (Medicare, age ≥65 years; n = 200), USD 10,267 for stroke commercial (n = 108), USD 16,280 for stroke Medicare (n = 113), USD 15,224 for peripheral arterial disease commercial (n = 170), and USD 15,182 for peripheral arterial disease Medicare (n = 208). Conclusion: These estimates can be used to study the cost-effectiveness of interventions proven to reduce these secondary events.
KW - Acute myocardial infarction, costs
KW - Costs, acute myocardial infarction/stroke
KW - Secondary atherosclerotic events, costs
KW - Stroke, costs
UR - http://www.scopus.com/inward/record.url?scp=3042588659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042588659&partnerID=8YFLogxK
U2 - 10.1159/000078602
DO - 10.1159/000078602
M3 - Article
C2 - 15159615
AN - SCOPUS:3042588659
SN - 1015-9770
VL - 18
SP - 8
EP - 15
JO - Cerebrovascular Diseases
JF - Cerebrovascular Diseases
IS - 1
ER -